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psoriasis were as follows: 13%were currently taking a biologic, 42%would consider
taking a biologic, 17% had previously taken a biologic, and 24% would not consider
taking a biologic. Hierarchical and non-hierarchical cluster analyses were applied
to themoment-to-moment affect traces that identified four unique patient clusters
(# 1-4). MDA was used to identify the five most impactful time periods within the
focus group audio segments. Cluster composition profiles were identified based
upon demographic information and patient responses to behavioral and attitudi-
nal questions. CONCLUSIONS: Understanding complex patient perspectives on
coping with disease is essential for delivering appropriate treatments over the
lifelong course of psoriasis. This novel methodology begins to bridge this knowl-
edge gap in understanding the patient-centered view of psoriasis. Furthermore, it
improves the likelihood of recommending treatments in alignment with the pa-
tient’s needs to improve health-related quality-of-life, productivity, and well-be-
ing.
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BURDEN OF DISEASE IN PATIENTS WITH DIAGNOSED PSORIASIS IN BRAZIL:
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OBJECTIVES: Currently in Brazil’s public healthcare, patients with psoriasis who
fail the available treatment options (phototherapy, methotrexate, acitretin and
cyclosporin) due to any cause, are experiencing a medical unmet need. This study
is aimed to assess comorbidity, quality of life (QoL), work/productivity loss (WPL),
and medical resource utilization in patients diagnosed with psoriasis (PdwP) in
Brazil. METHODS: A total of 12,000 individuals’ (age 18) self-reported data were
collected from2011National Health andWellness Survey (NHWS) in Brazil, a cross-
sectional representative sample of the adult population. QoL was measured by the
physical component score (PCS) and mental component score (MCS) of the Short
Form-12 (SF-12). WPL wasmeasured by the validatedWork Productivity and Activ-
ity Impairment instrument. Medical resource utilization was measured by health
care provider utilization, emergency room visits and hospitalization in the past 6
months. RESULTS: Of the 12,000 respondents, 205 (1.3%) were patients diagnosed
with psoriasis (PdwP) (53.0% women). Mean age was 40.2. Higher percentage of
co-morbidities was found among PdwP compared to patients not diagnosed with
psoriasis (PndP): headache (71% vs. 54%), sleep difficulties (50% vs.24%), anxiety
(50% vs.33%), insomnia (46% vs.22%), pain (42% vs.23%), skin allergies (40% vs.17%),
migraine (40%vs.20%), Heartburn (38% vs.23%) hay fever (37% vs.15%), nasal aller-
gies (33% vs.21%), depression (33% vs.16%), rhinitis (32%vs.11%), high blood pres-
sure (29% vs.16%), gingivitis (22%vs.6%), nail fungus (20%vs.7% ), dry eye (20%
vs.5%), anemia (19%vs.6%), diabetes type 1 or 2 (19%vs.4%). PdwPhad a lowermean
PCS (45.8 vs. 49.7) and MCS (42.3 vs.47.0), more visiting health practitioners (87.0%
vs.76.0%), emergency room visits (36.0%vs.22.0%), and hospitalizations for a med-
ical condition (21.0% vs.10.0%) over the past 6months compared to the PndP group.
Furthermore, PdwP reported higher presenteeism (30.4% vs.14.8%), work produc-
tivity loss (34.0% vs 18.9%) and activity impairment (36.5% vs.20.9%) compared to
the PndP group. All mentioned differences were statistically significant at p0.05.
CONCLUSIONS: From Brazilian NHWS results, PdwP suffer from impairment in
QoL, WPL, and more co-morbidities.
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PHARMACISTS’ BELIEFS REGARDING INTENTION TO UTILIZE PRESCRIPTION
DRUG MONITORING PROGRAM (PDMP) DATA
Fleming ML, Barner JC, Lajide CL
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To elicit modal salient behavioral beliefs, normative referents and
control beliefs of pharmacists regarding their intention to utilize online accessible
prescription drug monitoring program (PDMP) data when the validity of the pre-
scription or patient need is in question. METHODS: One hour focus groups were
conducted with a convenience sample of central Texas community pharmacists
with varied backgrounds and experiences. The theory of planned behavior was
used as the theoretical framework for the focus group guide, which consisted of
nine open-endedquestions to capture PDMPadvantages/disadvantages, important
influencers of utilization, and perceived facilitators or barriers. Content analysis
was performed on participants’ written responses to questions and focus groups’
transcripts. RESULTS: Three focus groups (Total N  23) were conducted. Nine
behavioral beliefs, eight normative referents and eight control beliefs were identi-
fied from the focus groups. Regarding advantages/disadvantages, pharmacists
most frequently mentioned that PDMP utilization would ensure appropriate con-
trolled medication therapy and prevent diversion. However, pharmacists were
fearful of potential increased liability as a result of having access to patients’ con-
trolled medication data. Important individuals or groups that pharmacists identi-
fied as influential to their decision to utilize PDMP data were regulatory agencies
(e.g., board of pharmacy), prescribers and pharmacy employers. The most impor-
tant belief that would facilitate PDMP utilization was interfacing the PDMP data-
base with their existing pharmacy software. The most frequently mentioned bar-
rier was lack of time to access data.CONCLUSIONS: The identification of items that
may influence pharmacists’ utilization of PDMP data when dispensing controlled
medications may be helpful to PDMP administrators’ implementation of online
accessible PDMPs. Increased utilization of PDMPs by pharmacists may lead to a
decrease in morbidity and mortality associated with controlled medication ther-
apy.
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OBJECTIVES: Purdue implemented a Risk Evaluation and Mitigation Strategy
(REMS) for Butrans (buprenorphine) Transdermal System that included distribu-
tion of a printed REMS Training in December 2010 to prescribers of extended re-
lease/long acting opioids to inform them on the risks and safe use of Butrans.
Prescribers who completed the training were asked to return a signed form with a
short post-test evaluation attached. We report on the results of the post-test eval-
uation by prescribers who completed the training between December 2010 and
February 2011. METHODS: The training guide was distributed to prescribers via
paper mail and field sales force in December 2010. The educational confirmation
form included 7 multiple choice questions with 26 response items measuring un-
derstanding of appropriate indication, dosing strength, storage and the risk factors
and signs of overdose, abuse and misuse. A multiple linear regression model was
computed to determine the mean total score and factors affecting it. RESULTS: A
total of 502 prescribers returned the formwhich included 36% general practitioners
and 64% specialists. The average score for correctly answering all the items was
97%. Average total score did not vary between general practitioners and specialists.
Prescribers scored relatively lower on items that individuals with a family history
of substance abuse are at increased risk of opioid abuse (82%) and individuals with
mental illness are at increased risk for opioid abuse (76%). CONCLUSIONS: Pre-
scribers completing the REMS training had high levels of understanding of the core
messages of the Butrans REMS; however, lower knowledge levels that mental ill-
ness and family history increase the risk of opioid abuse were identified. Another
survey of a random sample of Butrans prescribers from around the United States is
in progress.
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OBJECTIVES: Recent evidence suggests a higher risk of diabetes following smoking
cessation possibly related to the expectedweight gain. Quitting smoking, however,
remains recommended. The objective was to examine differences of smoking ces-
sation medication prescribing among smokers with different body weight levels
using theHealth andNutritional Examination Survey (NHANES) data.METHODS:A
retrospective cross-sectional study was conducted using the NHANES data from
1999 to 2008. The study included adults aged 18 yearswho self-reported currently
using tobacco. The outcome variable was receiving a cessationmedication (Bupro-
pion or Varenicline) vs. not. The independent variables included body mass index
(BMI), gender, age, race, education, marital status, family income, insurance type,
poverty income ratio (PIR), and health status. Multivariate logistic regression anal-
yses were conducted to assess the association between the main independent
variable (BMI) as well as socio-demographic and general health status characteris-
tics with the outcome variable. RESULTS: A total of 7743 adult smokers were in-
cluded. Among normal weight smokers, 2.72% were prescribed cessation medica-
tion, while 1.57% and 2.54% among overweight and obese smokers were prescribed
cessation medication, respectively. Logistic regression results showed that smok-
ers who were overweight were less likely to be prescribed cessation medications
than thosewithnormalweight (OR: 0.441, 95%CI: 0.212-0.915).Male smokers,white
race, having government insurance, college degree or above, PIR above average,
were significant factors of receiving a cessation medication. CONCLUSIONS: The
study documented a lower rate of smoking cessation medication use among over-
weight smokers compared to normal weight smokers. Whether this finding is re-
lated to physician or patient preferences remains uncertain. Future studies should
investigate the reasons for this discrepancy and develop effective interventions to
aid overweight smokers in quitting.
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OBJECTIVES: To examine differences in cessation medication prescribing among
smokers with different body weight levels using the National Ambulatory Medical
Care Survey (NAMCS) data. METHODS: A retrospective cross-sectional study was
conducted using the NAMCS data from 2005 to 2008. The study included visits with
smokers aged  18 and self-reported current tobacco use. The outcome variable
was being prescribed a cessation medication (Bupropion or Varenicline) vs. not.
The independent variables included body mass index (BMI), gender, age, race, ed-
ucation, insurance type, tobacco counseling, and health status. BMI splines were
used to describe different body levels. The knots of the BMI spline included normal,
overweight, obesity class I, II and III. Multivariate logistic regression analyses were
conducted to assess the association between the main independent variable of
BMI, as BMI splines in one model and a categorical variable in another model, as
well as socio-demographic and general health status characteristics with the out-
come variable. RESULTS: A total of 11,829 adult smoker visits were included.
Among normal weight visits, 6.28% had cessation medication prescriptions, while
4.70% and 3.89% among overweight and obese visits respectively had prescriptions.
Logistic regression showed that overweight (OR: 0.589, 95% CI: 0.351 – 0.987) and
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obese class III (OR: 0.399, 95% CI: 0.228 – 0.698) smokers were less likely to be
prescribed cessation medications compared to those with normal weight. The
weight spline had a significant decrease in the interval of overweight (OR: 0.853,
95% CI: 0.729-0.999). Male smokers, aged  65 years, white race, having private
insurance, having depression, cardiovascular diseases diagnosis, and tobacco
counseling, were significant predictors of having a smoking cessation prescription.
CONCLUSIONS: Overweight or obese smokers were less likely to be prescribed
cessationmedications. Future research is needed to investigate the reasons behind
this difference and develop interventions to help overweight and obese smokers
quit.
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USE OF NARCOTIC MEDICATIONS AMONG A LARGE COMMERCIALLY-INSURED
POPULATION IN THE UNITED STATES
Tian Y, Henderson RR, Frazee SG
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OBJECTIVES: Narcotic medications are increasingly becoming the most-abused
medicines in the United States, accounting for hundreds of deaths and thousands
of emergency room visits. The objective of this study is to examine the use of
narcoticmedications in a commercially insured population.METHODS: Retrospec-
tive pharmacy claims from a large US pharmacy benefit manager between January
2010 to December 2010 examined the prevalence, utilization and cost trend of
narcotic medications (GPI265). Only commercially insured patients with inte-
grated and funded prescription benefits were included in the analysis. RESULTS:
While females filled more narcotic prescriptions than males, male patients used
more expensive narcotic medications than their female counterparts ($58 per
script and $45 per script, respectively). The largest difference in cost per prescrip-
tion betweenmales and femaleswas in the 25-34 age groups ($64 per script and $33
per script for male and female, respectively). Within this age group, males spent
42% of their overall narcotic cost on Suboxone® and 16% on Oxycontin®, whereas
females only spent 21% on Suboxone®, 15% on hydrocodone-acetaminophen, and
14% on Oxycontin®. Males had lower generic fill rate (GFR) compared to their
female counterparts (86% and 95%, respectively). Consequently, the Per Member
per Year (PMPY) narcotic cost for males was $13.04 higher than females 24-35
years of age. As patient age increases, however, the trend is reversed: female
PMPY narcotic cost is $19.35 higher thanmale counterparts aged 75 or older. The
utilization and cost of narcotic medications differ by geographic region with
Oklahoma, Nevada, Utah, Ohio, and Alabama ranked as the Top 5 most costly
and Alabama, Oklahoma, Tennessee, Mississippi, and Wyoming having the
highest utilization. CONCLUSIONS:Results from this analysis can provide insights
into the utilization and cost of narcotic medications.
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OBJECTIVES: Currently, little is known about anti-obesity medication (AOM) utili-
zation. The purpose of this research was to explore predictors of utilization among
overweight and obese females within the MEPS database and to determine
whether use is primarily socially or medically driven. METHODS: A retrospective
case-control study design using 2003-2008 data from the Medical Expenditure
Panel Survey (MEPS) was performed. Datasets were generated by linking Full-Year
Consolidated Files to Prescribed Medicine Files in MEPS for each year. The Condi-
tions Files for each year were linked to ascertain whether or not respondents pos-
sessed a comorbidity of interest (diabetes, hyperlipidemia, hypertension). TheMul-
tum Lexicon File, released in Fall 2003, was used to identify AOM users in MEPS.
Logistic regression analysis was used to indicate whether obese/overweight re-
spondents take anAOM in that year, controlling for indicated medically necessary
or socially desirable related variables, and other potentially significant variables.
Proc means and proc freq in SAS 9.1 were used to generate descriptive statistics.
RESULTS: LR results show thatwomenwho are above the age of 35 are significantly
less likely to consume anti-obesity medications (Ages 36-49, OR0.570, p0.0082;
Ages 50-64, OR0.366, p0.001); oldest females are least likely to consume them
(Ages 65, OR0.072, p0.001). Married females are significantly more likely to
consume anti-obesity medications (OR1.695, p0.003). With unit increases in
BMI, females are 1.03 (p0.001)more likely to take anti-obesitymedications. Other
significant variables included education and possession of private insurance.
Dummy variables representing comorbidities were not significant predictors of
AOM use. CONCLUSIONS: Consumption of anti-obesity medications may be more
socially- rather than medically-driven, with more socially-related variables ap-
pearing significant in the model. Increased monitoring patients who receive these
medications is of urgent importance. AOMuse potentially involves adverse effects;
physicians’ role in prescribing these potentially dangerous medications may need
to be addressed.
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EVALUATION OF DAILY AVERAGE CONSUMPTION (DACON) OF OXYCODONE CR
AND OXYMORPHONE ER USING AN INTERRUPTED TIME SERIES ANALYSIS
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OBJECTIVES: Oxycodone controlled-release (CR) and oxymorphone extended-re-
lease (ER) are commonly prescribed, long-acting opioids, approved for twice-daily
dosing. We compared Daily Average Consumption (DACON) for oxycodone CR and
oxymorphone ER before and after the introduction of reformulated oxycodone CR.
METHODS: This was a retrospective claims database analysis using pharmacy
claims from the MarketScan® database during January 2010 through March 2011.
The Interrupted time series analysis was used to evaluate the impact of the intro-
duction of reformulated oxycodone CR on DACON of both drugs. RESULTS: Before
the introduction of reformulated oxycodone CR, the mean DACON for oxycodone
CR was higher than the mean DACON for oxymorphone ER in both highest and all
lower strengths pairs by 0.51 and 0.46 tablets, respectively. After the introduction,
the difference in mean DACON between the two drugs became 0.45 tablets for the
highest and 0.40 tablets for the lower strengths. Interrupted time series results
demonstrated that the immediate and overall impact on DACON of the reformu-
lated oxycodone CR was minimal, while there were no changes in the DACON for
oxymorphone ER as a result of the introduction. The estimated difference in aver-
age DACON for oxycodone CR decreased by 0.1 tablets or 3.7% (P 0.001) 6 months
after the new formulation was introduced. CONCLUSIONS: Mean DACON was
higher for oxycodone CR compared to oxymorphone ER by 0.4 tablets per day for all
dosage strengths for the entire study period. After the introduction of reformulated
oxycodone CR, the DACON for oxycodone CR was slightly mitigated; however,
there was a minimal impact on the mean difference between oxycodone CR and
oxymorphone ER.
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OBJECTIVES: Hospital admissions are frequent for Crohn=s Disease (CD) patients,
either to treat a flare-up or to have surgery. There are few data about CD in Latin
America. Some studies, however, have pointed to an increase in the prevalence
across the years. The aim of current the study is to analyze trends of the hospital
admission rate by CD in three Latin American countries: Brazil, Chile and Mexico.
METHODS: Data from the years 2001 to 2008 on primary diagnosis of Crohn=s
Diseasewere taken fromDatabases of Hospital Admission in Public Health System:
DATASUS in Brazil, DEIS in Chile and SINAIS in Mexico. Numbers of hospital ad-
mission by country, year and age rangewere collected andweighted by age specific
country population. Trends in hospital admission rates over timewere analyzed by
Poisson general estimation equations with an autoregressive correlation matrix.
Estimated coefficients were considered significant when p0.05. RESULTS: In all
countries the rate increased with the age. Mexico had the lower rates, which re-
main nearly constant over the years (0.09/100,000 inhabitants, pNS). In Chile, the
rate has increased over the years (0.45; annual risk ratio: 1.568 p0.001), differ-
ent fromBrazil that showed a decrease (-0111; annual risk ratio0.893; p0.001).
CONCLUSIONS: Reports from reference centers showed an increase in the number
of cases in the three countries; however in Mexico the number of patients still very
low. Therefore, the trend of hospital admission rates in Chile and Mexico seem to
be similar as the reported disease frequency. Regarding Brazil, a possible explana-
tion for the decrease in hospital admission could be changes in treatment prac-
tices, the financing of biological therapies in Public Health System since 2002. The
trends of hospital admission vary across the Latin America countries, and national
assistance programs for CD seem to have an impact on hospital admission rate.
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OBJECTIVES: The objective of this research was to conduct primary research with
US managed care decision-makers to understand their perceptions and manage-
ment expectations for pending biosimilar market availability in the United States.
METHODS: Explorative primary research (n20) was conducted with a sample of
Managed Care Organization (MCO) decision-makers composed of pharmacy and
medical directors, clinical pharmacists, and field experts involved in evaluating
expectations of biosimilar management. Interviews were conducted from January
to March 2011 and consisted of individual one-hour phone cponversations. Survey
development focused on addressing how biosimilar evaluations for plan coverage
will be made and vary by therapeutic class including testing of: Erythropoietin-
stimulating agents (ESA), cancer monoclonal antibodies (mAb), anti-tumor necro-
sis factor agents (anti-TNF), and granulocyte-colony stimulating factors (G-CSF).
Baseline knowledge that US payers had about biosimilars and abbreviated pathway
development was also tested. Qualitative survey methods for eliciting stated pref-
erences were used. RESULTS: Payers recognize differences between biosimilars
and small molecule generics in molecular structure andmanufacturing processes;
however, uncertainty exists around exact payer definitions for biosimilarity. Pay-
ers view biosimilars as alternative branded products rather than small molecule
generics. Research also indicated that contrary to review for small molecule gener-
ics, formulary review for biosimilar products will likely vary by class since different
drugs and indications may require different evidence. Specifically, variance in bio-
similarmanagement decisions will vary depending on the sensitivity level toman-
age the category. Payers expect biosimilar cost offsets within the range of 11-30%
from innovator brands. CONCLUSIONS: Presently, discussions about biosimilar
formulary review have been informal and high-levelt. Biosimilar product value
assessments will differ from the case of small molecule generics and coverage
policies will vary by class. Budgetary and economic impact is the major driver in
proposed utilization management controls, but will need to be balanced in light of
product comparisons in safety and efficacy.
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